Management of familial cancer: sequencing, surveillance and society
Authors:
- 14 October 2014
- journal article
- research article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 11 (12) , 723-731
Abstract
Many cancers, particularly those that arise in childhood, have a hereditary component. In this Perspectives article, the authors provide their views on how the increased adoption of high-throughput DNA sequencing technologies, which produce vast genetic data that is not necessarily limited to known cancer-susceptibility loci, and cancer surveillance strategies are influencing the clinical management of familial cancer. Important ethical issues relating to genetic counselling and disclosure of genetic information on disease susceptibility are discussed, and strategies for approaching these ethical dilemmas are proposed. The clinical management of familial cancer begins with recognition of patterns of cancer occurrence suggestive of genetic susceptibility in a proband or pedigree, to enable subsequent investigation of the underlying DNA mutations. In this regard, next-generation sequencing of DNA continues to transform cancer diagnostics, by enabling screening for cancer-susceptibility genes in the context of known and emerging familial cancer syndromes. Increasingly, not only are candidate cancer genes sequenced, but also entire 'healthy' genomes are mapped in children with cancer and their family members. Although large-scale genomic analysis is considered intrinsic to the success of cancer research and discovery, a number of accompanying ethical and technical issues must be addressed before this approach can be adopted widely in personalized therapy. In this Perspectives article, we describe our views on how the emergence of new sequencing technologies and cancer surveillance strategies is altering the framework for the clinical management of hereditary cancer. Genetic counselling and disclosure issues are discussed, and strategies for approaching ethical dilemmas are proposed.Keywords
This publication has 70 references indexed in Scilit:
- Ethics and Genomic Incidental FindingsScience, 2013
- Interpreting noncoding genetic variation in complex traits and human diseaseNature Biotechnology, 2012
- SomaticHIF2AGain-of-Function Mutations in Paraganglioma with PolycythemiaNew England Journal of Medicine, 2012
- A decade of exploring the cancer epigenome — biological and translational implicationsNature Reviews Cancer, 2011
- Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective studyEye, 2011
- Regular surveillance for Li-fraumeni syndrome: advice, adherence and perceived benefitsFamilial Cancer, 2010
- Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysisBreast Cancer Research and Treatment, 2010
- DICER1 Mutations in Familial Pleuropulmonary BlastomaScience, 2009
- Array Comparative Genomic Hybridization Copy Number Profiling: A New Tool for Translational Research in Solid MalignanciesSeminars in Radiation Oncology, 2008
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002